Collaborative Multi-institutional Experience in Comparing PD-L1 Immunohistochemistry Assays: Concordance of SP142 and 22C3 Immunoreactivity

被引：3
|
作者：
Karim, Lina Abdul [1 ]
Kallakury, Bhaskar V. S. [1 ]
Chahine, Joeffrey J. [1 ]
Sheehan, Christine E. [2 ]
Ross, Jeffrey S. [2 ,3 ]
机构：
[1] Medstar Georgetown Univ Hosp NW, Dept Pathol & Lab Med, Washington, DC 20057 USA
[2] Albany Med Coll, Dept Pathol, Albany, NY 12208 USA
[3] Fdn Med Inc, Cambridge, MA USA
来源：
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY | 2018年 / 26卷 / 02期
关键词：
D O I：
10.1097/PAI.0000000000000609
中图分类号：
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号：
100101 ;
摘要：
引用
收藏
页码：E22 / E22
页数：1
相关论文
共 50 条
  • [21] PD-L1 Expression in Metaplastic Breast Carcinoma (MBC) Using PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical (IHC) Assays
    Grabenstetter, Anne
    Jungbluth, Achim
    Frosina, Denise
    Hoda, Raza
    Weigelt, Britta
    Reis-Filho, Jorge
    Zhang, Hong
    Traina, Tiffany
    Robson, Mark
    Brogi, Edi
    Wen, Hannah
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 159 - 160
  • [22] Heterogeneity assessment of two PD-L1 clones: 22C3 and SP142 in patients with non-small cell lung cancer (NSCLC).
    Xu, Haipeng
    Li, Chao
    Gen, Lin
    Fang, Rong Xi
    Lin, Dong xian
    Huang, Yunjian
    Zhuang, Wu
    Miao, Qian
    Jiang, Kan
    Huang, Cheng
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry
    Rimm, David
    Han, Gang
    Taube, Janis M.
    Yi, Eunhee S.
    Bridge, Julia A.
    Flieder, Douglas B.
    Homer, Robert
    West, William W.
    Wu, Hong
    Roden, Anja C.
    Fujimoto, Junya
    Yu, Hui
    Anders, Robert
    Kowalewski, Ashley
    Rivard, Christopher
    Rehman, Jamaal
    Hirsch, Fred
    Wistuba, Ignacio I.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S249 - S249
  • [24] Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+NSCLC: Results from the randomized OAK study
    Gadgeel, S.
    Kowanetz, M.
    Zou, W.
    Hirsch, F. R.
    Kerr, K. M.
    Gandara, D. R.
    Barlesi, F.
    Park, K.
    McCleland, M.
    Koeppen, H.
    Ballinger, M.
    Sandler, A.
    Hegde, P. S.
    Rittmeyer, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
    Herbst, R. S.
    de Marinis, F.
    Giaccone, G.
    Reinmuth, N.
    Vergnenegre, A.
    Barrios, C. H.
    Morise, M.
    Felip, E.
    Andric, Z.
    Geater, S.
    Ozguroglu, M.
    Mocci, S.
    McCleland, M.
    Zou, W.
    Enquist, I.
    Komatsubara, K.
    Deng, Y.
    Kuriki, H.
    Spigel, D. R.
    Jassem, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 62 - 63
  • [26] Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer
    Lee, Seung Eun
    Park, Ha Young
    Lim, So Dug
    Han, Hye Seung
    Yoo, Young Bum
    Kim, Wan Seop
    JOURNAL OF BREAST CANCER, 2020, 23 (03) : 303 - 313
  • [27] Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms
    Sigurjonsdottir, Gudbjorg
    De Marchi, Tommaso
    Ehinger, Anna
    Hartman, Johan
    Bosch, Ana
    Staaf, Johan
    Killander, Fredrika
    Nimeus, Emma
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [28] Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms
    Gudbjörg Sigurjonsdottir
    Tommaso De Marchi
    Anna Ehinger
    Johan Hartman
    Ana Bosch
    Johan Staaf
    Fredrika Killander
    Emma Niméus
    Breast Cancer Research, 25
  • [29] Development of an immunohistochemistry assay for PD-L1 for using the 22C3 antibody in melanoma
    Roach, Charlotte
    Musser, Jeanette
    Ponto, Gary
    Toland, Grant
    Jansson, Malinka
    Emancipator, Kenneth
    Dolled-Filhart, Marisa
    Stanforth, Dave
    Kulangara, Karina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] PD-L1 (SP142) Immunohistochemistry in Clinical Metastatic Breast Carcinomas and its Association with Survival
    Shafi, Saba
    Challa, Bindu
    Parwani, Anil
    Li, Zaibo
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 192 - 194
12345